You are here

Article Text

Article menu

Download PDFPDF

Scientific Abstracts
Publication Only
COVID-19
AB1136 PREVALENCE OF COVID-19 IN SYSTEMIC LUPUS ERYTHEMATOSUS: A META-ANALYSIS
Free
  1. J. Wang1,2,
  2. S. X. Zhang2,3,4,
  3. X. Y. Yin2,5,
  4. B. R. Zhao2,5,
  5. Y. R. Shi1,2,
  6. J. Y. Meng2,5,
  7. Q. Y. Su2,3,4,
  8. X. F. LI3,
  9. C. Wang3
  1. 1Shanxi Medical University, Key laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan,Shanxi, China
  2. 2Shanxi Medical University, Academy of Microbial Ecology, Taiyuan,Shanxi, China
  3. 3The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan,Shanxi, China
  4. 4Shanxi Medical University, Key laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan,Shanxi, China
  5. 5Shanxi Medical University, Key laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan,Shanxi, China

Abstract

Background Novel Coronavirus pneumonia 2019 (COVID-19) is a systemic infectious disease with prominent involvement of the respiratory tract, due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1]. Systemic lupus erythematosus is charcterized by an aberrant immune response with the presence of circulating autoantibodies, lymphopenia, and proinflammatory[2]. They are immune-compromised and vulnerable to infections with immune-suppressants treatment. However, data regarding the impact of COVID-19 pandemic in patients with SLE and drug use were relatively scarce.

Objectives The prevalence of COVID-19 in SLE patients was estimated by means of meta-analysis, and the effect of the use of anti-rheumatic drugs on the clinical outcome of SLE patients with COVID-19 was investigated.

Methods Cross-sectional investigations and case series on SLE and COVID-19 published by CBM, CNKI, China Science and Technology Journal Database, Wan Fang Data, PubMed, Embase, Web of Science, Cochrane Library and Medline from its establishment to November 10, 2021 were searched. Random effects model was used to pool data. Heterogeneity and risk of bias was examined with I-squared index (I2) statistic. Inconsistency was evaluated by using the I2. Egger tests were used for the evaluation of potential publication bias (STATA v.12.0).

Results A total of 14 studies comprising 5365 patients were identified (Table 1). Overall prevalence of COVID-19 in SLE patients was 1.5% (95%CI: 1.2%-1.8%). Eight of the studies included patients who used hydroxychloroquine as part of their treatment regimen, with 29.8% (95%CI: 25.8%-33.8%) hospitalization rates and 14.6% (95%CI: 11.5%-17.8%) adverse outcome rates. Among patients treated with hydroxychloroquine throughout the course of disease, the prevalence was 0.7% (95%CI: 0.4%-1.0%, Figure 1).

View this table:
Table 1.

Summary of study characteristics of included records.

Figure 1.
Figure 1.

A:Forest map of a meta-analysis of COVID-19 prevalence in SLE patients.B: Forest map of a meta-analysis of hospitalization rates among patients treated with hydroxychloroquine.C:Forest map of meta-analysis of the rate of adverse outcomes in patients using hydroxychloroquine as part of a treatment regimen.D:Forest map of a meta-analysis of the prevalence of patients treated with hydroxychloroquine throughout the course.

Conclusion Patients with SLE had a higher risk of COVID-19. Hydroxychloroquine might benefit to reduce the overall hospitalization rate and prevalence rate of COVID-19, and alleviate inflammatory damage in the chronic stage of viral infection by inhibiting over activation of the immune system.

References [1]SCHULTZE J L, ASCHENBRENNER A C. COVID-19 and the human innate immune system [J]. Cell, 2021, 184(7): 1671-92.

[2]KIRIAKIDOU M, CHING C L. Systemic Lupus Erythematosus [J]. Ann Intern Med, 2020, 172(11): Itc81-itc96.

Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 82001740).

Disclosure of Interests None declared

https://doi.org/10.1136/annrheumdis-2022-eular.3423

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.